Upadacitinib vs. dupilumab in adults with moderate-to-severe atopic dermatitis: analysis of the Heads Up phase III trial

被引：0
|
作者：
Blauvelt, A. [1 ]
Teixeira, H. D. [2 ]
Simpson, E. L. [3 ]
Costanzo, A. [4 ,5 ]
De Bruin-Weller, M. [6 ]
Barbarot, S. [7 ]
Prajapati, V. H. [8 ,9 ,10 ,11 ,12 ,13 ]
Lio, P. [14 ,15 ]
Hu, X. [2 ]
Wu, T. [2 ]
Liu, J. [2 ]
Ladizinski, B. [2 ]
Chu, A. D. [2 ]
Eyerich, K. [16 ,17 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] AbbVie Inc, N Chicago, IL USA
[3] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA
[4] Humanitas Univ, Dept Biomed Sci, Dermatol Unit, Pieve Emanuele, Italy
[5] IRCCS, Humanitas Clin & Res Ctr, Rozzano, Italy
[6] Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands
[7] Nantes Univ, CHU Nantes, Dept Dermatol, Nantes, France
[8] Univ Calgary, Dept Med, Div Dermatol, Calgary, AB, Canada
[9] Univ Calgary, Dept Pediat, Div Community Pediat, Calgary, AB, Canada
[10] Univ Calgary, Dept Pediat, Div Pediat Rheumatol, Calgary, AB, Canada
[11] Skin Hlth & Wellness Ctr, Calgary, AB, Canada
[12] Dermatol Res Inst, Calgary, AB, Canada
[13] Prob Med Res, Calgary, AB, Canada
[14] Northwestern Univ, Feinberg Sch Med, Dept Dermatol, Chicago, IL 60611 USA
[15] Med Dermatol Associates Chicago, Chicago, IL USA
[16] Karolinska Inst, Stockholm, Sweden
[17] Karolinska Univ Hosp, Stockholm, Sweden
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2021年 / 185卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
489
引用
收藏
页码：E123 / E123
页数：1
相关论文
共 50 条
  • [31] Upadacitinib in moderate-to-severe atopic dermatitis: combined safety analysis of phase III studies (Measure Up 1, Measure Up 2 and AD Up)
    Guttman-Yassky, Emma
    Irvine, A. D.
    Silverberg, J. I.
    Papp, K. A.
    Paller, A. S.
    Waterhouse, B.
    Tenorio, A. R.
    Ladizinski, B.
    Chu, A. D.
    Liu, J.
    Reich, Kristian
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E123 - E124
  • [32] Comparative effectiveness of upadacitinib versus dupilumab for moderate-to-severe atopic dermatitis: A retrospective cohort study
    Yang, Yan
    Chen, Jiaoquan
    Xiong, Siyin
    Zhang, Jing
    Ye, Qianru
    Xue, Rujun
    Tian, Xin
    Zhong, Jiemin
    Zhu, Huilan
    Gao, Aili
    Liu, Yumei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 143
  • [33] A phase III study to investigate the efficacy and safety of abrocitinib and dupilumab in comparison with placebo in adults with moderate-to-severe atopic dermatitis
    Thaci, D.
    Bieber, T.
    Simpson, E. L.
    Silverberg, J. I.
    Paul, C.
    Sinclair, R.
    Pink, A. E.
    Kataoka, Y.
    Chu, C. -Y.
    DiBonaventura, M.
    Rojo, R.
    Antinew, J.
    Ionita, I.
    Forman, S.
    Zdybski, J.
    Biswas, P.
    Malhotra, B.
    Zhang, F.
    Valdez, H.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E72 - E73
  • [34] Methotrexate Versus Cyclosporine in Adults with Moderate-to-Severe Atopic Dermatitis: A Phase III Randomized Noninferiority Trial
    Goujon, Catherine
    Viguier, Manuelle
    Staumont-Salle, Delphine
    Bernier, Claire
    Guillet, Gerard
    Lahfa, Morad
    Le Bouedec, Marie-Christine Ferrier
    Cambazard, Frederic
    Bottigioli, David
    Grande, Sophie
    Dahel, Karima
    Berard, Frederic
    Rabilloud, Muriel
    Mercier, Catherine
    Nicolas, Jean-Francois
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2018, 6 (02): : 562 - +
  • [35] The patient burden of atopic dermatitis: insights from a dupilumab phase 2 clinical trial in adults with moderate-to-severe disease
    Mastey, V.
    Simpson, E.
    Bieber, T.
    Eckert, L.
    Wu, R.
    Ardeleanu, M.
    Graham, N.
    Pirozzi, G.
    Sutherland, E. R.
    EXPERIMENTAL DERMATOLOGY, 2014, 23 : 4 - 4
  • [36] The effect of dupilumab on biomarkers in a randomized phase 2b clinical trial in adults with moderate-to-severe atopic dermatitis
    Hamilton, J.
    Hamon, S.
    Simpson, E.
    Chaudhry, U.
    Swanson, B.
    Zhang, R.
    Graham, N.
    Pirozzi, G.
    Ardeleanu, M.
    Rizova, E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S224 - S224
  • [37] Efficacy and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: a subgroup analysis of the Measure Up 1, Measure Up 2 and AD Up phase III clinical trials
    Paller, A. S.
    Mendes-Bastos, P.
    Eichenfield, L. F.
    Soong, W.
    Lio, P.
    Prajapati, V. H.
    Platt, A. M.
    Teixeira, H. D.
    Liu, J.
    Ladizinski, B.
    Thyssen, J. P.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E128 - E129
  • [38] Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis
    Edwards, Steven J.
    Karner, Charlotta
    Jhita, Tracey
    Barton, Samantha
    Marceniuk, Gemma
    Yiu, Zenas Z. N.
    Wittmann, Miriam
    HEALTH TECHNOLOGY ASSESSMENT, 2024, 28 (04)
  • [39] Efficacy of upadacitinib and dupilumab on achieving stringent and composite skin and itch outcomes: an indirect comparison of adults with moderate-to-severe atopic dermatitis
    Armstrong, April W.
    Hong, H. Chih-Ho
    Calimlim, Brian M.
    Buessing, Marric G.
    Crowell, Marjorie M.
    Silverberg, Jonathan, I
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II26 - II27
  • [40] Preference for oral versus injectable treatment in adults with moderate-to-severe atopic dermatitis: results from the phase IIIb Heads Up clinical trial
    Prajapati, Vimal H.
    Eichenfield, Lawrence F.
    Schuttelaar, Marie L. A.
    Ladizinski, Barry
    Vigna, Namita
    Chen, Naijun
    Calimlim, Brian M.
    Costanzo, Antonio
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E81 - E82
12345